Are Robots the New Normal? Bet on these ETFs to Invest in the Future
Robotics is entering a new era as AI fuels humanoid adoption, with four ETFs offering diversified exposure to the sector's growth.
NOVT - Novanta Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$194.00
DETAILS
HIGH:
$194.00
LOW:
$194.00
MEDIAN:
$194.00
CONSENSUS:
$194.00
UPSIDE:
30.76%
Stock News
Connor Clark & Lunn Investment Management Ltd. Makes New Investment in Novanta Inc. $NOVT
Connor Clark and Lunn Investment Management Ltd. acquired a new position in Novanta Inc. (NASDAQ: NOVT) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 4,845 shares of the technology company's stock, valued at approximately $786,000. Several other large investors have
Novanta to Present at Baird Global Healthcare Conference on Tuesday, September 15, 2026
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, and John Lesica, Chief Operating Officer of Medical Solutions, are scheduled to present at the Baird Global Healthcare Conference on Tuesday, September 15, 2026, in New York, NY. About Novanta Novanta is a leading global supplier of core technology solutions that give medical a.
Recent Price Trend in Novanta (NOVT) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Novanta (NOVT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Are You Looking for a Top Momentum Pick? Why Novanta (NOVT) is a Great Choice
Does Novanta (NOVT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Novanta Inc. $NOVT Shares Bought by Bank of America Corp DE
Bank of America Corp DE increased its stake in Novanta Inc. (NASDAQ: NOVT) by 18.3% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 456,241 shares of the technology company's stock after acquiring an additional 70,728 shares during the
Amundi Purchases 3,516 Shares of Novanta Inc. $NOVT
Amundi increased its position in shares of Novanta Inc. (NASDAQ: NOVT) by 17.9% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 23,187 shares of the technology company's stock after buying an additional 3,516 shares during the quarter. Amundi owned 0.07% of
Novanta Q2 Earnings Call Highlights
Novanta (NASDAQ: NOVT) reported second-quarter results marked by 9% organic sales growth, expanding margins and higher operating cash flow, while raising its full-year outlook following the late-July closing of its Riverpoint Medical acquisition. Chair and Chief Executive Officer Matthijs Glastra said reported revenue grew 10% year over year during the quarter, while adjusted EBITDA increased 16%
Novanta Q2 Earnings Call Highlights
Novanta NASDAQ: NOVT reported second-quarter results marked by 9% organic sales growth, expanding margins and higher operating cash flow, while raising its full-year outlook following the late-July closing of its Riverpoint Medical acquisition.
Novanta Inc. (NOVT) Q2 2026 Earnings Call Transcript
Novanta Inc. (NOVT) Q2 2026 Earnings Call Transcript
Novanta (NOVT) Tops Q2 Earnings and Revenue Estimates
Novanta (NOVT) came out with quarterly earnings of $0.89 per share, beating the Zacks Consensus Estimate of $0.83 per share. This compares to earnings of $0.76 per share a year ago.
Novanta Announces Financial Results for the Second Quarter 2026
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the second quarter 2026. Financial Highlights Three Months Ended (In millions, except per share amounts) July 3, June 27, 2026 2025 GAAP Revenue $ 265.8 $ 241.0 Operating Income $ 18.1 $ 14.9 Net Income $ 12.5 $ 4.5 Diluted EPS $ 0.30 $ 0.12.
Conestoga SMid Cap Composite Q2 2026 Portfolio Review
West Pharmaceuticals stock moved higher following another quarter of broad-based growth, driven by continued demand for high-value biologics packaging and proprietary delivery components. Tyler Technologies underperformed during the quarter despite delivering solid financial results that met management's guidance. We were attracted to Knowles' accelerating organic growth, expanding margins, and exposure to several attractive long-term secular trends.
Analyzing Vicor (NASDAQ:VICR) & Novanta (NASDAQ:NOVT)
Novanta (NASDAQ: NOVT - Get Free Report) and Vicor (NASDAQ: VICR - Get Free Report) are both mid-cap computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings. Analyst Recommendations This is a breakdown of
Will Novanta (NOVT) Beat Estimates Again in Its Next Earnings Report?
Novanta (NOVT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Novanta (NOVT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Novanta (NOVT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
American Capital Management Inc. Has $44.16 Million Stake in Novanta Inc. $NOVT
American Capital Management Inc. lowered its position in shares of Novanta Inc. (NASDAQ: NOVT) by 2.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 373,874 shares of the technology company's stock after selling 7,992 shares during the period. Novanta
Novanta Completes Acquisition of Riverpoint Medical
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today announced that it has completed the acquisition of Riverpoint Medical (“Riverpoint Medical” or “Riverpoint”) from Arlington Capital Partners. Riverpoint is a category leader in high-growth minimally invasive surgical consumables, including advanced surgical fibers and related technologies for sports medicine, trauma and.
Novanta Inc. Announces Schedule of Second Quarter 2026 Earnings Release and Conference Call
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its second quarter 2026 results after the close of U.S. financial markets on Wednesday, August 5, 2026. The Company will host a conference call on Thursday, August 6, 2026, at 8:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the con.
Novanta (NOVT) Upgraded to Buy: What Does It Mean for the Stock?
Novanta (NOVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Price Targets
Novanta price target raised to $194 from $180 at Baird
$194.00
(was $168.29)
Robert W. Baird
Novanta price target raised to $180 from $173 at Baird
$180.00
(was $164.34)
Quinn Fredrickson
·
Robert W. Baird
Novanta price target raised to $150 from $138 at Baird
$150.00
(was $134.67)
Robert Mason
·
Robert W. Baird
Novanta price target lowered to $160 from $169 at Baird
$160.00
(was $143.37)
Robert W. Baird
Novanta price target raised to $175 from $170 at Baird
$175.00
(was $174.36)
Robert Mason
·
Robert W. Baird